Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
ThrombocytosisIron-Deficiency Anemia
Interventions
DRUG

FERINJECT® (Ferric carboxymaltose)

FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.

DRUG

Placebo

Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.

Trial Locations (1)

1090

Univ. clinic for Internal Medicine, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vifor Pharma

INDUSTRY

NCT00882414 - Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) | Biotech Hunter | Biotech Hunter